Anteris Technologies Glb (AVR) closed at $5.58 on November 5, 2026, down 8.8% from the previous close, on volume of 1,645,082 shares (30-day average 1,481,281).
Data as of November 5, 2026.
5-Nov-2026
Anteris Technologies Global Corp. (AVR) Receives a Buy from Cantor Fitzgerald
TipRanks (Tue, 3-Nov 7:59 AM ET)
Anteris spotlights single-digit gradients for medium-size DurAVR THV in 22-patient EMBARK cohort
Market Chameleon (Mon, 2-Nov 2:32 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Mon, 2-Nov 6:51 AM ET)
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
Globe Newswire (Sun, 1-Nov 2:59 PM ET)
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
Globe Newswire (Tue, 27-Oct 6:00 AM ET)
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
Globe Newswire (Mon, 19-Oct 9:12 PM ET)
Anteris to Present at September Healthcare Investor Conferences
Globe Newswire (Mon, 31-Aug 2:45 PM ET)
Anteris Technologies Announces Results for the Second Quarter of 2026
Globe Newswire (Tue, 11-Aug 7:00 PM ET)
Medtronic’s Strategic Stake Signals Confidence in Anteris’ $200M Offering—What Does It Mean for AVR?
Market Chameleon (Wed, 21-Jan 4:55 AM ET)
Market Chameleon (Wed, 21-Jan 2:06 AM ET)
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
Anteris Technologies Glb trades on the NASDAQ stock market under the symbol AVR.
As of November 5, 2026, AVR stock price declined to $5.58 with 1,645,082 million shares trading.
AVR has a beta of 1.80, meaning it tends to be more sensitive to market movements. AVR has a correlation of 0.09 to the broad based SPY ETF.
AVR has a market cap of $543.82 million. This is considered a Small Cap stock.
Last quarter Anteris Technologies Glb reported $1 million in Revenue and -$.30 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.09.
The top ETF exchange traded funds that AVR belongs to (by Net Assets): IWM, VXF, IWN, VTWO, SCHA.
AVR has outperformed the market in the last year with a return of +32.5%, while the SPY ETF gained +9.3%. However, in the most recent history, AVR shares have underperformed the stock market with its stock returning -30.7% in the last 3 month period and -7.0% for the last 2 week period, while SPY has returned -4.5% and -4.1%, respectively.
AVR support price is $5.84 and resistance is $6.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVR shares will trade within this expected range on the day.
